BioE3 Policy
The Indian government's BioE3 policy aims to drive innovation in the biotechnology sector.
Key Focus Areas: Biomanufacturing facilities, bio-AI hubs, and bio-foundries.
A focus on developing and administering drugs tailored to individual patients.
Boosting the development of biologics like gene therapy and cell therapy.
Organ-on-Chip Technology
Human-relevant 3D culture models (NAMs), like organ-on-chips, are promising for precision therapeutics.
The global organ-on-chip market is expected to reach $1.4 billion by 2032 due to increased R&D investment.
Organ-on-chips mimic the body's conditions in a lab, revolutionizing healthcare by replacing animal testing for drug development.
Challenges in Traditional Drug Development
Developing a new drug takes nearly a decade and costs $2.3 billion.
Many drug candidates fail in clinical trials due to animal model inaccuracies.
Organ-on-Chip as a Solution
Organ-on-chips offer a more accurate platform for preclinical drug testing without animals.
Improved Efficacy and Toxicity Assessment: Provides better understanding of drug effects.
Helps reduce animal testing.
Paves the way for personalized medicine.
Can accelerate drug development and potentially reduce costs.
Investments and Developments
The U.S. National Institutes of Health allocated $100 million for organ-on-chip development.
Several companies are developing microphysiological systems for various organs.
The FDA Modernization Act 2.0 and EU regulations support NAMs and organ-on-chips.
Many pharmaceutical companies are exploring organ-on-chip technology.
Challenges for India
Developing organ-on-chip technology requires collaboration among experts from various fields.
Establishing dedicated centers can foster collaboration and knowledge exchange.
Navigating regulatory frameworks for organ-on-chip development is essential.
Building a skilled workforce is crucial for driving the technology forward.
India can play a significant role in the development and adoption of organ-on-chip technology by establishing dedicated centers, fostering collaboration, and navigating regulatory challenges.
This will contribute to improving healthcare, boosting the economy, and increasing self-sufficiency in a strategically important domain.
COMMENTS